Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A molecular atlas of cellular vulnerability and resilience in the parkinsonian striatum. [snRNA_seq]

ABSTRACT: The progressive degeneration of dopaminergic projections to the striatum is a key disease mechanism in Parkinson’s disease (PD). To define the cellular landscape in the parkinsonian striatum, we mapped the cellular transcriptome in early and progressive PD mouse models and in human PD stages. Our analyses revealed significant transcriptomic changes across both neuronal and glial populations, with astrocytes and oligodendrocytes exhibiting distinct disease-associated gene expression profiles. Notably, progressive dopamine depletion uncovered differential neuronal vulnerability, identifying eccentric type striatal projection neurons (SPNs) and Chst9-expressing direct pathway SPNs as the most resilient subtypes in mice and humans. This cross-species molecular atlas of the cell-state dynamics in the parkinsonian striatum uncovers the selectively vulnerable and resilient cell types that can inspire new treatment strategies.

ORGANISM(S): Mus musculus

PROVIDER: GSE298848 | GEO | 2026/06/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

A molecular atlas of cellular vulnerability and resilience in the parkinsonian striatum.

Project description:The progressive degeneration of dopaminergic projections to the striatum is a key disease mechanism in Parkinson’s disease (PD). To define the cellular landscape in the parkinsonian striatum, we mapped the cellular transcriptome in early and progressive PD mouse models and in human PD stages. Our analyses revealed significant transcriptomic changes across both neuronal and glial populations, with astrocytes and oligodendrocytes exhibiting distinct disease-associated gene expression profiles. Notably, progressive dopamine depletion uncovered differential neuronal vulnerability, identifying eccentric type striatal projection neurons (SPNs) and Chst9-expressing direct pathway SPNs as the most resilient subtypes in mice and humans. This cross-species molecular atlas of the cell-state dynamics in the parkinsonian striatum uncovers the selectively vulnerable and resilient cell types that can inspire new treatment strategies.

2026-06-01 | GSE298680 | GEO

Identification of potential biomarkers for patients with neurodegenerative parkinsonian syndromes using serum cytokine microarray analysis; series 6

Project description:Background: Microarray technology may offer a new opportunity to gain insight into disease-specific global protein expression profiles. The present study was performed to apply a serum cytokine-array to screen for potential molecular biomarkers for Parkinson's disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Methodology/Principal Findings: Serum samples were obtained from patients with clinical diagnoses of PD (n=117), MSA (n=31) and PSP/CBS (n=38) and 99 controls. Cytokine profiles of sera of patients and controls were analyzed with a semiquantitative human cytokine antibody array. In a next step, significantly altered cytokines were individually validated by immunoassays. The cytokine array revealed a significantly altered expression of 12 cytokines. Immunoassay validation confirmed a significant increase of PDGF-BB in PSP/CBS, MSA and PD and a decrease of Prolactin in PD (Kruskal-Wallis p<0.05). A multivariate analysis taking into account diagnoses anti-Parkinsonian treatment, sex and age revealed that PDGF-BB levels were influenced only by the diagnoses (p<0.001), whereas Prolactin levels were influenced only by anti-Parkinsonian treatment (p<0.001). These findings could be corroborated by a subgroup analysis in untreated patients. Conclusions/Significance: In our unbiased cytokine array screening approach we found PDGF-BB to be elevated in PSP/CBS, MSA and PD. Increased PDGF-BB levels might be of relevance in a model of molecular biomarkers for Parkinsonian syndromes. Screen serum samples from patients with Parkinson's disease, progressive supranuclear palsy, corticobasal syndrome, multisystem atrophy and controls for deregulation of serum proteins using a cytokine-array detecting 174 secreted signaling proteins.

2011-11-23 | E-GEOD-32037 | biostudies-arrayexpress

Identification of potential biomarkers for patients with neurodegenerative parkinsonian syndromes using serum cytokine microarray analysis; series 8

2011-11-23 | E-GEOD-32040 | biostudies-arrayexpress

Identification of potential biomarkers for patients with neurodegenerative parkinsonian syndromes using serum cytokine microarray analysis; series 7

2011-11-23 | E-GEOD-32039 | biostudies-arrayexpress

Identification of potential biomarkers for patients with neurodegenerative parkinsonian syndromes using serum cytokine microarray analysis; series 8

2011-11-23 | GSE32040 | GEO

Identification of potential biomarkers for patients with neurodegenerative parkinsonian syndromes using serum cytokine microarray analysis; series 7

2011-11-23 | GSE32039 | GEO

Identification of potential biomarkers for patients with neurodegenerative parkinsonian syndromes using serum cytokine microarray analysis; series 6

2011-11-23 | GSE32037 | GEO

Microarray Analysis of Striatal Tissue derived RNA isolated from Chronic Levodopa (L-DOPA) treated Parkinsonian and Dyskinetic (LID) Rats as compared to Parkinsonian Disease (PD) Control Rats

Project description:We compared differential gene expression between Striatal tissue derived RNA isolated from Chronic Levodopa (L-DOPA) treated (L-Dopa methyl ester plus benserazide were given at 25 mg/kg and 6.25 mg/kg dose) - Parkinsonian and Dyskinetic Rats (LID Rats) for 8 days as compared to Parkinsonian Disease Control Rats (PD Control Rats). The hypothesis tested in the present study was that whether Inflammation has any role in Chronic Levodopa Induced Dyskinesia in Rats of Parkinson's disease model- as compared to Control Rats with Prakinson's disease by performing differential gene expression and pathway analyses.

2020-03-26 | GSE139438 | GEO

Epigenetic resetting in the Parkinson's disease entail histone modification remodeling.

Project description:Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons (DN) in the substantia nigra and disrupted cellular maintenance. Here, we demonstrate that NDST3-mediated epigenetic reprogramming halts neuronal degeneration and restores motor function in a PD animal model. Following NDST3 administration, DN and associated circuits in the substantia nigra and striatum show marked revitalization, accompanied by significant alleviation of PD-like motor deficits. Integrative single-cell and spatial RNA sequencing with ChIP sequencing reveal that NDST3-driven reactivation of pathways linked to neuronal survival, synaptic integrity, steering compromised cells toward a resilient phenotype. By recalibrating the epigenetic landscape, NDST3 fosters cellular maintenance and functional recovery within key motor circuits. These findings highlight NDST3’s therapeutic potential as epigenetic modulator in PD. Our findings provide insights into the mechanisms underlying neuronal revitalization and underscore the promise of NDST3 as a novel agent for restoring brain function in neurodegenerative conditions.

2026-03-16 | PXD067971 | Pride

Transcription profiling of mouse multiple brain regions for a MPTP model of Parkinsons disease

Project description:In Parkinsonâ??s disease (PD), the progressive loss of substantia nigra dopamine cells has been associated with their vulnerability to oxidative stress, inflammation, and mitochondrial dysfunction. To identify multiple gene transcription alterations that may potentially underlie early stages of related degenerative processes in brain, we used the subcrhonic MPTP mouse model of PD and microarray analysis at 4 days post-MPTP when neurotoxic activity is maximal. Since PD results in gene changes throughout the brain, we assessed MPTP's effects in multiple regions: frontal cortex, striatum and midbrain. Experiment Overall Design: Mus musculus adults were randomly assigned to either MPTP or saline treatment groups. Brain regions of interest (frontal cortex, striatum and midbrain) were dissected from both groups for RNA extraction and hybridization on Affymetrix microarrays.

2008-10-26 | E-GEOD-7707 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data